Omalizumab for AsthmaSkip to the navigation
Omalizumab (Xolair) is a medicine approved by the U.S. Food and Drug Administration (FDA) for use in people age 12 and older who have moderate or severe persistent asthma. This medicine costs a lot more than any of the standard treatments for asthma.
This medicine may help reduce asthma episodes, improvepeak expiratory flow (PEF), and reduce the need for other medicines. It may also reduce emergency room visits and hospital stays. But more study is needed.
Omalizumab is given as a shot. The dose depends on your body weight and IgE level.
Your doctor may recommend this medicine if:
- Your asthma is not well controlled after using inhaled corticosteroids and long-acting beta2-agonists or leukotriene pathway modifiers for 3 months. People who use oral or injected corticosteroids or who need high doses of inhaled corticosteroids for daily control can also consider using this medicine.
- You have severe allergic asthma and your symptoms aren't relieved by avoiding allergens or taking other medicines.
Severe allergic reactions, includinganaphylaxis, can occur with omalizumab, but this is rare. So people who get this medicine are watched for 2 hours after they get their first 2 doses. They should also carry epinephrine in case they have an allergic reaction after treatment.
Other Works Consulted
- Chung KF, et al. (2014). International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal, 43(2): 343-373. DOI: 10.1183/09031936.00202013. Accessed March 11, 2014.
Primary Medical Reviewer E. Gregory Thompson, MD - Internal Medicine
Adam Husney, MD - Family Medicine
Specialist Medical Reviewer Rohit K. Katial, MD - Allergy and Immunology
Current as ofDecember 6, 2017
To learn more about Healthwise, visit Healthwise.org.
© 1995-2018 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.